title: Effects of angiogenic factors, antagonists, and podocyte injury on development of proteinuria in preeclampsia.
abstract: Proteinuria is universal to all patients with preeclampsia. We examined the urinary podocytes in women with preeclampsia (n = 14), gestational hypertension (n = 14), and normal pregnancy. Maternal serum and urinary concentrations of vascular endothelial growth factor (VEGF), placental growth factor (PlGF), and the antiangiogenic factor soluble fms-like tyrosine kinase 1 (sFlt-1) were detected. These concentrations were used to evaluate the urinary excretion of podocytes and the alteration of angiogenic factors and to assess their relationships to proteinuria in preeclampsia. Our studies suggest that the urinary podocyte number and angiogenic factors are correlated with random urine albumin/creatinine ratio and blood pressure. Receiver-operating characteristic (ROC) curves of serum and urinary PlGF and the PlGF/sFlt-1 ratio as well as the presence of podocyturia confirmed their usefulness in distinguishing preeclamptic and normotensive pregnant women. In addition, combinations of serum or urinary PlGF or podocyturia tests in parallel or in series provided the best clue for identifying patients with preeclampsia. We considered that the dysregulation of angiogenic factors and its subsequent podocyte injury may contribute to the mechanism of proteinuria development in preeclampsia.
authors.affiliation: Division of Nephrology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
authors.forename: Guixiang
authors.initials: G
authors.lastname: Chen
authors.forename: Lihong
authors.initials: L
authors.lastname: Zhang
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Jin
authors.forename: Yunjiao
authors.initials: Y
authors.lastname: Zhou
authors.forename: Jianying
authors.initials: J
authors.lastname: Niu
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.forename: Yong
authors.initials: Y
authors.lastname: Gu
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D042501:Angiogenic Proteins / Q000097:blood* / Q000652:urine*; D015415:Biomarkers / Q000097:blood / Q000652:urine; D016022:Case-Control Studies; D003404:Creatinine / Q000652:urine; D005260:Female; D006801:Humans; D000072483:Placenta Growth Factor; D050199:Podocytes / Q000473:pathology*; D011225:Pre-Eclampsia / Q000097:blood / Q000209:etiology* / Q000473:pathology / Q000652:urine; D011237:Predictive Value of Tests; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000097:blood / Q000652:urine; D011507:Proteinuria / Q000097:blood / Q000209:etiology* / Q000473:pathology / Q000652:urine; D012372:ROC Curve; D012307:Risk Factors; D016482:Urinalysis; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000652:urine; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000097:blood / Q000652:urine; D055815:Young Adult
chemical_list: D042501:Angiogenic Proteins; D015415:Biomarkers; C000608036:PGF protein, human; D011257:Pregnancy Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000072483:Placenta Growth Factor; D003404:Creatinine; C501162:FLT1 protein, human; D040281:Vascular Endothelial Growth Factor Receptor-1